Entering text into the input field will update the search result below

Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp

Jul. 26, 2022 12:32 AM ETAgios Pharmaceuticals, Inc. (AGIO)3 Comments
William Meyers profile picture
William Meyers


  • Agios sold its first successful commercial drug to Servier for $2 billion.
  • Launch of second drug, Pyrukynd, is underway.
  • Large cash balance and platform potential sweeten the picture.
Red eritrosit blood count medical concept

ismagilov/iStock via Getty Images

Agios Pharmaceuticals (NASDAQ:AGIO) has twice graduated from being a clinical stage company to being a commercial stage company in the last few years. In 2018 it received FDA approval for the cancer therapy Tibsovo. Agios then sold its entire cancer division

This article was written by

William Meyers profile picture
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of AGIO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (3)

Thanks for the update. Long AGIO.
WM, thank you for a fine analysis, it's now on my watch list.
Their pipeline appears sparse - yet, their R&D cash burn is steep. Why would this be a good investment ?
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.